Welcome to our dedicated page for Sunshine Biopharma SEC filings (Ticker: SBFM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sunshine Biopharma Inc. filings document the reporting record of a public pharmaceutical company with Canadian generic-drug operations and proprietary oncology and antiviral development programs. Form 8-K disclosures cover operating results, material events, warrant solicitation arrangements, auditor changes, officer transitions and shareholder actions affecting common-stock matters.
Proxy and annual-meeting materials describe board elections, board committees, corporate governance, executive compensation, principal shareholders, related-party transactions, auditor ratification and equity incentive plan matters. The company’s filing record also includes late-filing notices for annual reports and capital-structure disclosures involving outstanding warrants and potential stock-split authority.
Sunshine Biopharma Inc. (SBFM) has filed a Form S-1 to register 25,477,133 shares of common stock issuable upon exercise of its outstanding Series B Warrants. The warrants, issued in a February 15, 2024 public offering, currently have a per share exercise price of $1.2202 and expire on February 15, 2029. The registration is intended to permit the warrants to be exercised for cash rather than on a cashless basis.
If all Series B Warrants are exercised for cash at the current price, Sunshine Biopharma would receive gross proceeds of $31,087,198, or approximately $31 million net, which it plans to use for general corporate purposes, including working capital. The company’s common stock trades on Nasdaq under “SBFM,” with a last reported sale price of $1.27 on August 27, 2026. The prospectus highlights Nasdaq listing risk: the company recently effected multiple reverse stock splits and remains vulnerable to delisting for bid-price noncompliance and to a proposed new $5 million Market Value of Listed Securities requirement that it does not currently meet. Sunshine Biopharma also discloses 29,512,762 outstanding warrants, indicating potential future dilution.
Sunshine Biopharma Inc. (SBFM) reported that on August 25, 2026, director Dr. Andrew Keller informed the company he will not seek or accept reelection to the Board of Directors after his current term ends. His term will expire at the company’s next annual shareholder meeting, at which point he will leave the board.
L1 Capital Global Opportunities Master Fund, Ltd. reports beneficial ownership of 111,535 Common Units of Sunshine Biopharma Inc., representing 4.99% of the class. This percentage is based on 2,123,635 Common Units outstanding as of May 28, 2026, as stated in a Definitive 14C Information Statement.
The filing notes exposure through 5,344,378 Series B Warrants and 400,000 Series C Warrants, each exercisable into common stock but subject to a 4.99% beneficial ownership limitation. L1 Capital holds sole voting and dispositive power over the 111,535 Common Units. Directors David Feldman and Joel Arber may be deemed beneficial owners under Rule 13d-3, but each disclaims beneficial ownership for all other purposes. The amendment also references an earlier filing covering 1,000,000 Common Units purchased on May 18, 2026.
Sunshine Biopharma Inc., a Colorado-based pharmaceutical company with generic and OTC operations in Canada and proprietary oncology/antiviral programs, reported second-quarter 2026 results. Q2 2026 revenue was $9,263,687, slightly below $9,410,230 a year earlier, as terminated distribution agreements reduced sales. Gross profit for the quarter was $2,426,682, and the company recorded a net loss of $1,564,048 ($1.15 per share).
For the first six months of 2026, revenue totaled $17,352,452 versus $18,311,571 in 2025, with a net loss of $2,807,917 ($2.95 per share). Operating expenses declined year over year, helped by the absence of a prior-period intangible impairment and lower consulting and R&D costs, partly offset by higher legal fees. Cash and cash equivalents were $13,748,301 at June 30, 2026, and total assets were $33,632,901.
Financing activities in the first half of 2026 provided $7,804,185 of cash, including a May 19, 2026 public offering of 1,200,000 units and warrant exercises. Subsequent to quarter-end, the company established a $4,000,000 at-the-market offering and raised $1,722,555 in net proceeds, received a U.S. patent for its coronavirus protease inhibitors, and continued development of its K1.1 mRNA liver cancer and SBFM-PL4 antiviral candidates.
Sunshine Biopharma Inc. received an updated Schedule 13G/A from Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC reporting their beneficial ownership in the company’s common stock. As of June 30, 2026, they may be deemed to beneficially own 235,697 shares of common stock issuable upon exercise of a warrant, representing 9.99% of the outstanding common stock. This percentage is calculated using 2,123,635 shares outstanding as of May 28, 2026 plus the 235,697 warrant shares. Additional warrant shares are contractually blocked from exercise above ownership caps of 9.99% for one warrant and 4.99% for another, which limits the reportable beneficial ownership.
NATAN DAVID reported acquisition or exercise transactions in this Form 4 filing.
Sunshine Biopharma Inc. director Natan David received a stock award of 58,300 shares of common stock on August 7, 2026. The award was granted at a stated price of $0.00 per share and increased his directly held position to 68,300 common shares following the transaction. A footnote clarifies that this represents a stock award to the reporting person.
Sunshine Biopharma Inc. reports that, as a result of recent sales of its common stock under a previously disclosed at-the-market offering, the exercise price of its outstanding Series B Warrants has been reduced to $1.2202. This exercise price remains subject to further adjustment under the terms of the Series B Warrants.
Sunshine Biopharma Inc. is initiating an at-the-market common stock offering of up to $4,000,000 under a Sales Agreement with Aegis Capital Corp., acting as exclusive sales agent. Shares may be sold from time to time on Nasdaq as defined in Rule 415.
The company will pay Aegis a 3.0% cash commission on gross proceeds and reimburse specified expenses, and Aegis will be deemed an underwriter. Net proceeds are intended for general corporate purposes, including working capital. Under General Instruction I.B.6 of Form S-3, primary offerings are limited to one-third of non-affiliate market value while it remains below $75 million.
Sunshine Biopharma Inc. entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp., allowing the company to sell shares of its common stock from time to time for an aggregate offering price of up to $4,000,000 in at-the-market offerings through or to Aegis as exclusive sales agent.
Sales may be effected directly on or through the Nasdaq Capital Market or other existing trading markets under Rule 415(a)(4). Aegis will receive a 3.0% commission on gross proceeds plus certain reimbursed expenses. Neither party is obligated to transact, and both may terminate the agreement. The shares will be issued under the company’s shelf registration statement on Form S-3 (File No. 333-284142), effective January 15, 2025, and a July 20, 2026 prospectus supplement.
Sunshine Biopharma Inc., through its wholly owned subsidiary Nora Pharma Inc., entered into an agreement of transaction and mutual release with Nora’s former president, Malek Chamoun, on July 8, 2026. Under this agreement, Sunshine Biopharma agreed to pay Mr. Chamoun CAD$1,500,000 (approximately US$1,058,565) in full and final settlement of a dispute between the parties. The agreement functions as a comprehensive release, aiming to conclude outstanding claims between the company, Nora, and Mr. Chamoun.